Related Experiment Video

Updated: Mar 26, 2026

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice
08:52

Intravital Microscopy of Tumor-associated Vasculature Using Advanced Dorsal Skinfold Window Chambers on Transgenic Fluorescent Mice

Published on: January 19, 2018

14.8K

Tumor resistance to vascular disrupting agents: mechanisms, imaging, and solutions

Wenjie Liang1, Yicheng Ni2, Feng Chen1

  • 1Department of Radiology, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Oncotarget
|January 27, 2016
PubMed

Insights

Vascular disrupting agents (VDAs) show promise for solid tumors, but resistance causes recurrence. Understanding resistance mechanisms like hypoxia and exploring combination therapies are key for effective VDA treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Tumor Biology

Background:

  • Vascular disrupting agents (VDAs) represent a novel therapeutic strategy for solid tumors.
  • VDAs rapidly shut down tumor blood flow, leading to tumor necrosis.
  • A residual tumor rim after VDA treatment is a primary cause of cancer recurrence.

Purpose of the Study:

  • To review the mechanisms of solid tumor resistance to VDAs.
  • To discuss methods for monitoring VDA resistance.
  • To explore strategies for overcoming VDA resistance in cancer treatment.

Main Methods:

  • Literature review of studies on VDA mechanisms and resistance.
  • Analysis of factors contributing to tumor resistance.
  • Examination of monitoring techniques and combination therapies.

Main Results:

  • Tumor resistance to VDAs is multifactorial, involving hypoxia, tumor-associated macrophages, and circulating endothelial progenitor cells.
  • Magnetic resonance imaging (MRI) markers can monitor VDA resistance.
  • Combination strategies are crucial for managing resistance.

Conclusions:

  • Overcoming VDA resistance requires a comprehensive approach.
  • Combining VDAs with antiangiogenic agents, chemotherapy, radiotherapy, or radioimmunotherapy can improve outcomes.
  • Sequential dual-targeting internal radiotherapy offers a potential solution for resistant tumors.
Keywords:
imagingresistancesolutionsvascular disrupting agents

More Related Videos

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis09:42

Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis

Published on: June 26, 2019

9.3K
A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics12:09

A Novel High-resolution In vivo Imaging Technique to Study the Dynamic Response of Intracranial Structures to Tumor Growth and Therapeutics

Published on: June 16, 2013

12.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K